Top

Current Hepatology Reports

Published in:

01-09-2019 | Acute Liver Failure | Drug-Induced Liver Injury (P Hayashi, Section Editor)

Drug-Induced Liver Injury Due to Nonsteroidal Anti-inflammatory Drugs

Author: Paul A Schmeltzer

Published in: Current Hepatology Reports | Issue 3/2019

Abstract

Purpose of Review

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a heterogeneous group of medications intended to treat a variety of inflammatory diseases. While they are generally regarded as safe and most known for their potential gastrointestinal and renal side effects, cases of hepatotoxicity have been reported. This review summarizes the US and international literature regarding the incidence of NSAID-induced DILI and the biochemical signature of specific NSAIDs.

Recent Findings

Multiple studies have identified diclofenac as one of the more common culprits of NSAID-induced DILI. A genetic predisposition to DILI has been identified with diclofenac and lumiracoxib.

Summary

While NSAID-induced hepatotoxicity is rare, the potential for serious hepatotoxicity exists especially with certain agents such as diclofenac. An improved understanding of pharmacogenomics and post-marketing surveillance/monitoring is needed to reduce the risk of this DILI.

Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014;23:43–50. https://doi.org/10.1002/pds.3463.CrossRefPubMed

Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5. https://doi.org/10.1053/jhep.2002.34857.CrossRefPubMed

Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–25. https://doi.org/10.1053/j.gastro.2013.02.006.CrossRefPubMed

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–34. https://doi.org/10.1053/j.gastro.2008.09.011.CrossRefPubMedPubMedCentral

Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stoltz A, Fontana RJ, et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 2016;36(4):603–9. https://doi.org/10.1111/liv.13032.CrossRefPubMed

Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol. 2005;3(5):489–98. https://doi.org/10.1053/S1542-3565(04)00777-3.CrossRefPubMed

Laine L, Goldkind L, Curtis SP, Connors LG, Yangqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009;104:356–62. https://doi.org/10.1038/ajg.2008.149.CrossRefPubMed

Daniels AM, Gibbs LM, Herndon CM. Elevated transaminases with topical diclofenac: a case report. J Pain Palliat Care Pharmacother. 2019;15:1–4. https://doi.org/10.1080/15360288.2018.1546257.CrossRef

Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430–40. https://doi.org/10.1002/hep.20205.CrossRefPubMed

10.

•• Lazarska KE, Dekker SJ, Vermeulen NP, Commandeur JN. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett. 2018;284:70–8. https://doi.org/10.1016/j.toxlet.2017.11.038 Suggests pathophysiologic and genetic mechanism for one of the NSAIAs most often reported to cause DILI. CrossRefPubMed

11.

LiverTox: http://livertox.nlm.nih.gov.

12.

Lee SM, O’Brien CJ, Williams R, Whitaker S, Gould SR. Subacute hepatic necrosis induced by piroxicam. Br Med J (Clin Res Ed). 1986;293:540–1. https://doi.org/10.1136/bmj.293.6546.540.CrossRef

13.

Hepps KS, Maliha GM, Estrada R, Goodgame RW. Severe cholestatic jaundice associated with piroxicam. Gastroenterology. 1991;101:1737–40.CrossRefPubMed

14.

Sherman KE, Jones C. Hepatotoxicity associated with piroxicam use. Gastroenterology. 1992;103:354–5.CrossRefPubMed

15.

Xie W, Wang Q, Gao Y, Pan CQ. Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report. BMC Gastroenterol. 2018;18:142. https://doi.org/10.1186/s12876-018-0869-9.CrossRefPubMedPubMedCentral

16.

•• Zoubek ME, Gonzalez-Jimenez A, Medina-Caliz I, Robles-Diaz M, Hernandez N, Romero-Gomez M, et al. High prevalence of ibuprofen drug-induced liver injury in Spanish and Latin-American registries. Clin Gasteroenterol Hepatol. 2018;16:292–4. https://doi.org/10.1016/j.cgh.2017.07.037 Reports a much higher prevalence of DILI in Spain than in the USA, perhaps due to differences in over-the-counter dosing. CrossRef

17.

Ali S, Pimentel JD, Ma C. Hepatobiliary. Pancreat Dis Int. 2011;10(5):552–6. https://doi.org/10.1016/S1499-3872(11)60093-3.CrossRef

18.

Zimmerman H. Effects of aspirin and acetaminophen on the liver. Arch Intern Med. 1981;141:333–41.CrossRefPubMed

19.

Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye’s Syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340:1377–82.CrossRefPubMed

20.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA. 2000;284:1247–55.CrossRef

21.

El Hajj II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J Gastroenterol. 2009;15(31):3937–9.CrossRefPubMedPubMedCentral

22.

Soni P, Shell B, Cawkwell LC, Ma H. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Cur Med Res Opin. 2009;25:1841–51. https://doi.org/10.1185/03007990903018279.CrossRef

23.

Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42:711–4. https://doi.org/10.1038/ng.632.CrossRefPubMed

24.

Donati M, Conforti A, Lenti MC, Capuano A, Bortolami O, Motola D, et al. Risk of acute and serious liver injury associated to nimuselide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016;82(1):238–48. https://doi.org/10.1111/bcp.12938.CrossRefPubMedPubMedCentral

25.

Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095–101. https://doi.org/10.1080/00365520510023846.CrossRefPubMed

26.

Andrade RL, Lucena MI, Fernandez MC, Pelaez G, Pachkora K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–21. https://doi.org/10.1053/j.gastro.2005.05.006.CrossRefPubMed

27.

Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. MULTICEnter, prospective study. Hepatology. 2010;52(6):2065–76. https://doi.org/10.1002/hep.23937.CrossRefPubMedPubMedCentral

Title: Drug-Induced Liver Injury Due to Nonsteroidal Anti-inflammatory Drugs
Author: Paul A Schmeltzer
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Acute Liver Failure
Diclofenac
Piroxicam
Naproxen
Ibuprofen
Meloxicam
Celecoxib
Published in: Current Hepatology Reports / Issue 3/2019
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-019-00477-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2019

Global Epidemiology of Drug-Induced Liver Injury (DILI)

Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment

Strategies for Global Elimination of Chronic HBV Infection: 2019 Update

The Role of Traditional Chinese Medicines (TCM) and Other Complementary and Alternative Medicines (CAM) in the Management of Chronic Hepatitis B

Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection

Regional and Racial Differences in Drug-Induced Liver Injury

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage